Head-to-head evidence
10-1074 vs 3BNC117
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV envelope · full HIV pipeline
10-1074
Developed by Gilead Sciences and partners
NCT03707977 · Phase 1/2 · completed
This was a small, nonrandomized, open-label study without a comparator arm, enrolling 30 children overall and evaluating viral-load and safety outcomes descriptively. The primary viral outcomes were reported as 11 of 25 below 400 copies/mL and 10 of 25 below 40 copies/mL at Week 24, but there was no controlled comparison or formal significance test.
Next expected readout: September 2029 · NCT07820813 (registry estimate)
3BNC117
Developed by Frontier Biotechnologies and partners
NCT03041012 · Phase 2 · completed
The trial randomly assigned 60 participants to four groups, including standard antiretroviral therapy alone and combinations containing 3BNC117, but treatment was not blinded. Its primary outcomes were virologic and reservoir measures rather than hard clinical outcomes, and the registry provides no results showing whether any primary comparison was met.
Next expected readout: December 2026 · NCT05300035 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: 10-1074's landscape · 3BNC117's landscape